Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
NCT ID: NCT03632668
Last Updated: 2019-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
38 participants
INTERVENTIONAL
2018-09-28
2019-01-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
NCT03586037
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
NCT06448962
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
NCT05202405
A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282
NCT06858865
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
NCT06747936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
AD-2071 10/20mg
AD-2071 10/20 mg tablet
AD-2072 80/5mg
AD-2072 80/5mg tablet
AD-2071 10/20mg + AD2072 80/5mg
AD-2071 10/20 mg + AD-2072 80/5mg tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-2071 10/20mg
AD-2071 10/20 mg tablet
AD-2072 80/5mg
AD-2072 80/5mg tablet
AD-2071 10/20mg + AD2072 80/5mg
AD-2071 10/20 mg + AD-2072 80/5mg tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight between 50 kg and 90 kg and body mass index (BMI) between 18.0 kg/m2 and 27.0 kg/m2
Exclusion Criteria
* Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery
* HDL values less than 35 mg/dL
* AST, ALT values over than 1.5 times of ULN at screening
* A person who has a history of drug abuse or who has positive result for an abuse drug in a urine screening test
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
In-Jin Jang, M.D.,Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-207DDI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.